Skip to search formSkip to main contentSkip to account menu

RP5063

Known as: RP5000 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia
RP5063 is a multimodal dopamine (D)‐serotonin (5‐HT) stabilizer with a high affinity for D2/3/4 and 5‐HT1A/2A/2B/7 receptors and… 
2017
2017
Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients
RP5063, a multimodal dopamine (D)–serotonin (5‐HT) stabilizer, possesses high affinity for D2/3/4 and 5‐HT1A/2A/2B/2C/6/7… 
Review
2017
Review
2017
A Closer Look at the Preclinical Experience of RP5063 in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, debilitating condition with a 5to 7-year survival rate of approximately 50… 
2009
2009
Clinical News
Phase 1 Results of New Putative Antipsychotic RP5063 Reported Results were presented at the recent New Clinical Drug Evaluation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)